Estrella advances STARLIGHT-1 to Phase II after DSMB OK; 100% CR in high-dose cohort

Estrella Immunopharma, Inc.

DSMB recommends Phase II at RP2D after no treatment-related SAEs in Phase I (n=9).
High-dose cohort achieved 100% complete response (CR) rate at Month 1 in evaluable patients.
Phase II expansion will evaluate EB103 in relapsed/refractory B-cell NHL at RP2D.
Majority of Phase I patients were high-risk, including one with CNS lymphoma.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.